%0 Journal Article
%A Forschner, Andrea
%A Kähler, Katharina C
%A Gschnell, Martin
%A Langan, Ewan A
%A Weishaupt, Carsten
%A Meiss, Frank
%A Thoms, Kai-Martin
%A Wahl, Renate U
%A Göppner, Daniela
%A Garzarolli, Marlene
%A Sachse, Michael
%A Schlaak, Max
%A Reitmajer, Markus
%A Kellner, Ivonne
%A Gesierich, Anja
%A Mohr, Peter
%A Meier, Friedegund
%A von Wasielewski, Imke
%A Herbst, Rudolf
%A Utikal, Jochen
%A Pföhler, Claudia
%A Ulrich, Jens
%A Terheyden, Patrick
%A Kaatz, Martin
%A Haferkamp, Sebastian
%A Leiter, Ulrike
%A Ugurel, Selma
%A Weichenthal, Michael
%A Berking, Carola
%A Gutzmer, Ralf
%A Schadendorf, Dirk
%A Nanz, Lena
%A Loquai, Carmen
%T Treatment at the end of life in patients with advanced melanoma. A multicenter DeCOG study of 1067 patients from the prospective skin cancer registry ADOReg.
%J Frontiers in immunology
%V 16
%@ 1664-3224
%C Lausanne
%I Frontiers Media
%M DKFZ-2025-00535
%P 1509886
%D 2025
%X Although systemic therapies have improved considerably over the last decade, up to 50
%K Humans
%K Melanoma: drug therapy
%K Melanoma: mortality
%K Melanoma: therapy
%K Male
%K Female
%K Registries
%K Skin Neoplasms: drug therapy
%K Skin Neoplasms: mortality
%K Aged
%K Middle Aged
%K Prospective Studies
%K Aged, 80 and over
%K Terminal Care: methods
%K Immune Checkpoint Inhibitors: therapeutic use
%K Immune Checkpoint Inhibitors: adverse effects
%K Adult
%K Treatment Outcome
%K BRAF and MEK inhibitors (Other)
%K end of life (Other)
%K immune checkpoint inhibitors (Other)
%K ipilimumab (Other)
%K melanoma (Other)
%K nivolumab (Other)
%K Immune Checkpoint Inhibitors (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40066437
%2 pmc:PMC11891187
%R 10.3389/fimmu.2025.1509886
%U https://inrepo02.dkfz.de/record/299594